To conclude, we demonstrated that enhanced glycolysis limited the efficiency of gemcitabine, while suppressing the glycolysis process with melatonin treatment or silencing of ENO1 promoted the cytotoxic effect of gemcitabine on BLCA cells. The gene discussed is ENO1; the disease is bladder transitional cell carcinoma.